SEATTLE, March 21, 2017 /PRNewswire/ -- Sound Pharmaceuticals, Inc., (SPI) is pleased to announce that it has been awardedup to $1.6M from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The CFFT development award will support the initial testing
The STOP Ototoxicity study will be led by Patrick Flume, MD, Professor of Medicine and Pediatrics at MUSC in Charleston, and will enroll a total of 100 subjects at multiple US sites. Dr. Flume is an international expert in CF and pulmonary disease and has co-chaired the development of the CF Foundation's care guidelines on the treatment of pulmonary exacerbations. "We are thrilled to have the support of the CF Foundation and Dr. Flume on this groundbreaking study of tobramycin-induced ototoxicity," said Jonathan Kil, MD, SPI's Co-Founder, CEO and Chief Medical Officer. CF patients are extremely vulnerable to ototoxicity because they receive repeated courses of aminoglycosides, such as tobramycin or amikacin, through inhaled and injected routes of administration, starting at a very young age. "This is the first comprehensive US study of ototoxicity in the CF population and we are pleased to be leading it," said Dr. Flume.
Ototoxicity is common side effect in medical treatments involving chemotherapy, antibiotics and loop diuretics. The combination of these classes of drugs can be contraindicated, especially in conditions where kidney function is impaired. These highly ototoxic medications can result in permanent, and often progressive inner ear disease. In some cases, the ototoxicity becomes dose-limiting and results in moderate hearing loss that requires a hearing aid, or severe to profound hearing loss that requires a cochlear implant. Currently, there are no FDA approved drugs for the prevention or treatment of any type of sensorineural hearing loss or tinnitus including ototoxicity or Meniere's disease.
Contact: www.soundpharma.com or Jonathan Kil, MD, email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sound-pharmaceuticals-announces-16-million-award-from-cystic-fibrosis-foundation-therapeutics-to-prevent-and-treat-the-hearing-loss-and-tinnitus-associated-with-antibiotic-use-300426694.html
SOURCE Sound Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Winking is a non-verbal form of communication that involves the rapid closing and opening of one ...
Anti-aging ingredients can prevent signs of aging such as wrinkles, dryness, and sagging of skin. ...
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...View All